Clinical Trial Suggests Vitamin C Improves Survival in Precancerous Blood Disorders and Early-Stage Blood Cancers

A Phase 2 EVITA clinical trial, published in the American Cancer Society journal CANCER, suggests that daily 1,000 mg oral vitamin C supplementation could improve survival in individuals with precancerous blood disorders and early-stage blood cancers. Patients receiving the supplement experienced fewer adverse events and showed a promising survival advantage, along with changes in immune signaling molecules associated with more favorable outcomes.